Back to search
FDAFDA · Food and drugs·Recall number D-0100-2025

Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx only, a) 30 count (NDC 68001-414-04) and b) 1,000 count (NDC 68001-414-08) bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories

Published December 11, 2024 · Recall initiated: November 14, 2024

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit

What to do

Voluntary: Firm initiated · Letter

Recall details

Manufacturer
Amerisource Health Services LLC
Distributor
PA, OH, PR
Lot
a) 30 count; Lot, expiry: DT3023019B, DT3023020A, exp 01/31/2025 b) 1000 count; Lot, expiry: DTB23098A, exp 08/31/2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Sell products like this?

Recalert watches your whole catalog for recalls like this one, automatically.

Start free — no card